Europe's aversion to GM crops has killed investors' appetites for agricultural research. Even in the UK, historically a world leader in this field, it is almost impossible to commercialise agricultural biotechnology of any kind.
BioXell, an Italian spin-out from Roche, said it has raised €10.5 million in funding from an extension of its Series C round which was first closed in October, 2004. TVM Capital, one of Germany’s biggest venture capital funds, led the financing.
On March 7 in Paris, we open our Science|Business Roundtable of leaders in European industry and academia, to debate and propose new ideas to improve the climate for innovation in Europe. One immediate suggestion is that Europeans do better at communications.
Scientists at Innsbruck Medical University have performed a great service to mankind by demonstrating that beer has important health-promoting properties.
Europe is lousy at reaping the commercial benefits of its R&D. To spur reform, Science|Business is preparing a “manifesto” of policy measures for technology transfer and innovation. What’s needed? A revolution.
Sarissa Biomedical, a spin-out from the University of Warwick, that has designed a sensor to give an early warning of fetal hypoxia during birth, is looking for investors to strike licensing agreements.
Philips Research has developed a woodstove for cooking in rural communities in developing countries – and is looking for partners to bring this technology to the market.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.